Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AnaptysBio, Inc. (ANAB : NSDQ)

• Company Description    AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. Number of Employees: 136

• Price / Volume Information    Yesterday's Closing Price: $23.88 Daily Weekly Monthly 20 Day Moving Average: 556,308 shares Shares Outstanding: 29.38 (millions) Market Capitalization: $701.61 (millions) Beta: -0.27 52 Week High: $41.31 52 Week Low: $12.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.27% 7.64% 12 Week 41.30% 23.82% Year To Date 80.36% 70.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10770 Wateridge Circle Suite 210 - San Diego,CA 92121 USA ph: 858-362-6295 fax: - investors@anaptysbio.com http://www.anaptysbio.com

• General Corporate Information    Officers Daniel Faga - President; Chief Executive Officer and Director Dennis Mulroy - Chief Financial Officer Dennis Fenton - Director Rita Jain - Director Oleg Nodelman - Director Peer Information AnaptysBio, Inc. (CORR.) AnaptysBio, Inc. (RSPI) AnaptysBio, Inc. (CGXP) AnaptysBio, Inc. (BGEN) AnaptysBio, Inc. (GTBP) AnaptysBio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 032724106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 29.38 Most Recent Split Date: (:1) Beta: -0.27 Market Capitalization: $701.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.45 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.67 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 20.76 Price/Cash Flow: - Price / Sales: 6.27 EPS Growth vs. Year Ago Period: 21.95% vs. Previous Quarter: -77.78% Sales Growth vs. Year Ago Period: 286.84% vs. Previous Quarter: -35.59% ROE 06/30/25 - - 03/31/25 - -282.47 12/31/24 - -272.87 ROA 06/30/25 - - 03/31/25 - -30.79 12/31/24 - -32.09 Current Ratio 06/30/25 - - 03/31/25 - 8.25 12/31/24 - 9.51 Quick Ratio 06/30/25 - - 03/31/25 - 8.25 12/31/24 - 9.51 Operating Margin 06/30/25 - - 03/31/25 - -125.70 12/31/24 - -159.10 Net Margin 06/30/25 - - 03/31/25 - -125.70 12/31/24 - -159.10 Pre-Tax Margin 06/30/25 - - 03/31/25 - -125.66 12/31/24 - -159.10 Book Value 06/30/25 - - 03/31/25 - 1.15 12/31/24 - 2.33 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©